LONG.
trend has been going straight up, uncertainty with NCE took it lower for great entry point. Now that is over straight back up and great sales.
LDL is THE most important levels. You want your LDL Low so you are NOT at risk of heart failure or heart attack. No Dr. is going to give Lovaza, now that there is Vascepa.
Good Link. Nice DD.
sales going to grow fast now.
samayc09== No offense but you shouldn't be trading. BASF is a Supplier for AMRN Not any form of competition./ Wow do your DD man.
Adam F. --Smart Man.
Sales already proving that. Do the DD, Vascepa is a superior drug.
sqeeze to begin.
should have them next week.
in and long
in and long
I thin it also be great to let everyone think AA in June and then it comes in May..no meeting scheduled per call.
5 stars
chris just told you..take a hint
5 stars
couldnt agree more $
Yahoo News 5/9/13
Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments
Documents Requested by FDA for Accelerated Approval Consideration of Eteplirsen Will Be Submitted This Month; Clinical, Regulatory, and Manufacturing Activities Continue to Progress for Eteplirsen and Additional Duchenne Muscular Dystrophy Drug Candidates; Strong Cash Balance of $175 Million at Quarter-End